• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Editor's Pick

US imposing new export controls on biotech equipment over China concerns

by January 15, 2025
written by January 15, 2025

By David Shepardson

WASHINGTON (Reuters) – The U.S. Commerce Department said Wednesday it is imposing new export controls on biotechnology equipment and related technology because of national security concerns tied to artificial intelligence and data science.

Washington has raised concerns that China could use U.S. technology to strengthen military capabilities and help design new weapons through AI. The department said the laboratory equipment could be used for “human performance enhancement, brain-machine interfaces, biologically-inspired synthetic materials, and possibly biological weapons.”

The new export controls, which restrict shipments to China and other countries without a U.S. license, are for high-parameter flow cytometers and certain mass spectrometry equipment, which Commerce said can “generate high-quality, high-content biological data, including that which is suitable for use to facilitate the development of AI and biological design tools.”

This is the latest effort by Washington to restrict U.S. technology to China. On Monday, Commerce moved to further restrict AI chip and technology exports from China aimed at helping the United States maintain its dominant status in AI by controlling it around the world.

U.S. lawmakers have been considering a number of proposals to keep Americans’ personal health and genetic information from foreign adversaries and aim to push U.S. pharmaceutical and biotech companies to lessen their reliance on China for everything from drug ingredient manufacturing to early research.

Last week, U.S. lawmakers called on the Commerce Department to consider restricting the export of U.S. biotechnology to the Chinese military, citing concerns Beijing could weaponize it.

The Chinese Embassy in Washington last week said Beijing “firmly opposes any country’s development, possession or use of biological weapons.”

In August, U.S. lawmakers called on the Food and Drug Administration to ramp up scrutiny of U.S. clinical trials conducted in China, citing the risk of intellectual property theft and the possibility of forced participation of members of China’s Uyghur minority group.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
US health officials set to ban Red No. 3 food coloring- Bloomberg News
next post
Trump’s new SEC leadership poised to kick start crypto overhaul, sources say

You may also like

China central bank conducts 1.7 trln yuan of...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

ECB president fears loss of central bank independence

January 27, 2025

European tech shares tumble as China’s AI push...

January 27, 2025

Futures slip as investors eye China’s latest AI...

January 27, 2025

Markets may be repeating the mistake of 2019,...

January 27, 2025

How billionaire Caltagirone could influence Italy’s banking M&A...

January 27, 2025

How Italy’s MPS went from near collapse to...

January 27, 2025

Analysis-To weather Trump, emerging market investors look to...

January 27, 2025

Chinese AI startup DeepSeek overtakes ChatGPT on Apple...

January 27, 2025
Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!








    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • China outlines more controls on exports of rare earths and technology

      October 10, 2025
    • Paramount acquires Bari Weiss’ The Free Press, naming her the top editor of CBS News

      October 7, 2025
    • YouTube to pay $24 million to settle Trump lawsuit

      October 1, 2025
    • Charlie Javice sentenced to 7 years in prison for fraudulent $175M sale of aid startup

      October 1, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (651)
    • Stock (6,426)

    Latest News

    • China outlines more controls on exports of rare earths and technology
    • Paramount acquires Bari Weiss’ The Free Press, naming her the top editor of CBS News

    Popular News

    • Ski patrol strike at largest resort in US leads to long lines, closed trails
    • Oppenheimer initiates coverage of these 5 storage & infrastructure stocks

    About The Significant deals

    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy